Welcome to our dedicated page for Livanova news (Ticker: LIVN), a resource for investors and traders seeking the latest updates and insights on Livanova stock.
LivaNova PLC reports developments as a global medical technology company focused on selected neurological and cardiac conditions. Company news commonly covers revenue results and guidance, performance in its Cardiopulmonary and Epilepsy businesses, and updates tied to medical-device commercialization and clinical evidence.
Recurring product themes include VNS Therapy for drug-resistant epilepsy, real-world evidence from the CORE-VNS study, and obstructive sleep apnea technology using proximal hypoglossal nerve stimulation. Updates also include FDA regulatory decisions, including premarket approval for the aura6000 System, investor conference appearances, and business update calls.
LivaNova (Nasdaq: LIVN) announced that CMS assigned VNS Therapy for drug-resistant epilepsy to New Technology APC 1580 for new patient implants and moved end-of-service procedures to Level 5 APC, effective Jan. 1, 2026. CMS will increase hospital outpatient payments by about 48% for NPIs and 47% for EOS versus 2025 rates. LivaNova said the reimbursement change should improve hospital economics, reduce a barrier to procedure penetration, and expand patient access to VNS Therapy, which the company reports showed median seizure reductions of 80% and 95% in CORE-VNS at 36 months.
LivaNova (Nasdaq: LIVN) presented a strategic roadmap and 2030 financial targets at its 2025 Investor Day on November 12, 2025.
Key targets include high-single-digit-plus revenue CAGR to 2030, adjusted operating margin above 20% over the next three years and targeting high‑twenties by 2030, EPS CAGR in the low double digits to mid‑teens, and adjusted free cash flow conversion above 80%.
Growth pillars are maximizing Cardiopulmonary and Epilepsy cores, scaling Obstructive Sleep Apnea (OSA) with an independent U.S. commercial launch planned for 2027, and optional upside from Difficult‑to‑Treat Depression contingent on CMS coverage. OSA is projected to reach $200M–$400M revenue by 2030 and >25% adjusted operating margin, with break‑even expected by 2029.
LivaNova (Nasdaq: LIVN) reported Q3 2025 revenue of $357.8M, up 12.5% reported, 11.0% constant-currency and 12.5% organic versus prior year. Cardiopulmonary revenue rose 18.0% driven by Essenz perfusion system sales and consumables; Neuromodulation rose 6.9%. U.S. GAAP diluted EPS was $0.49; adjusted diluted EPS was $1.11. Adjusted operating income increased to $80.4M from $63.6M; operating cash flow was $85.1M and adjusted free cash flow was $62.0M. The company raised full‑year 2025 guidance: revenue growth to 8.5%–9.5% (constant currency), adjusted EPS to $3.80–$3.90, and adjusted free cash flow to $160M–$180M. Essenz commercial launch initiated in China and a new director was appointed.
LivaNova (Nasdaq: LIVN) will present a general business update at the Wolfe Research Healthcare Conference in New York on Mon., Nov. 17, 2025 at 2:40 p.m. ET.
Chief Executive Officer Vladimir Makatsaria and Chief Financial Officer Alex Shvartsburg will take part in a fireside chat. The live webcast is open to registered viewers via www.livanova.com/events, with attendees advised to log on ~10 minutes early. A replay will be posted on the LivaNova website within 24 hours after the live presentation.
LivaNova (Nasdaq: LIVN) will release its third-quarter 2025 results prior to a conference call on Wednesday, Nov. 5, 2025 at 1:00 p.m. London time (8:00 a.m. ET). The company will host an audiocast of the call at www.livanova.com/events and recommends logging on about 10 minutes early to confirm setup. Telephone access: +1 833 470 1428 (U.S.) or +1 929 526 1599 (outside U.S.) using access code 817099. A replay will be posted in the Investors section of the LivaNova website immediately after the event.
LivaNova (Nasdaq: LIVN) will present scientific data at the International Surgical Sleep Society (ISSS) 2025 Annual Meeting in Indianapolis on Oct 9–10, 2025. Presentations include a five‑year analysis of the THN‑3 randomized controlled trial and 12‑month top‑line data from the OSPREY follow‑on RCT. OSPREY reported a 65% responder rate at 12 months (≥50% AHI improvement and AHI 20). The company will also host a breakfast symposium on and feature an oral presentation and poster describing proximal hypoglossal nerve stimulation (p‑HGNS) therapy and the aura6000 System.
Presenters include Dr. Alan Schwartz, Dr. Ofer Jacobowitz, and Dr. Atul Malhotra.
LivaNova (Nasdaq: LIVN) has appointed Donald (Don) Zurbay to its Board of Directors, where he will serve on the Audit and Compliance Committee. Zurbay brings over 30 years of experience in finance, accounting, and strategy, most recently serving as President and CEO of Patterson Companies after being its CFO. He previously spent nearly 13 years at St. Jude Medical in various leadership roles, including CFO.
Zurbay currently serves on the Board of Directors at Sight Sciences, chairing its Audit Committee. He holds a bachelor's degree in business accounting from the University of Minnesota. With this appointment, the LivaNova Board now comprises 11 Directors.
LivaNova (Nasdaq: LIVN), a leading medical technology company, has announced its upcoming Investor Day scheduled for November 12, 2025, from 9 a.m. to 1 p.m. EST in New York City. The event will feature presentations from key executives, including CEO Vladimir Makatsaria and CFO Alex Shvartsburg, who will outline the company's strategic roadmap and growth initiatives.
The event will be accessible both in-person (requiring advance registration) and via webcast on the company's website. Presentation materials and a replay will be made available in the Investors section of LivaNova's website following the event.
LivaNova (Nasdaq: LIVN), a medical technology company, announced its leadership team's participation in two upcoming healthcare conferences. CEO Vladimir Makatsaria and CFO Alex Shvartsburg will present business updates at the Baird 2025 Global Healthcare Conference on September 9 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10 in New York City.
Both presentations will be accessible via webcast on the company's website, with replays available for 90 days after each event. Interested parties must register to attend the webcasts and should log on 10 minutes before the start time.
LivaNova (Nasdaq: LIVN) has launched its Essenz™ Perfusion System in China, marking a significant expansion in the world's second-largest market for heart-lung machines. The system, which received NMPA approval, has already supported over 100,000 patients globally since its February 2023 launch.
The Essenz system includes the next-generation heart-lung machine, Patient Monitor, and In-Line Blood Monitor, designed in collaboration with over 300 perfusionists worldwide. The launch is particularly significant given China's projected 185,000 adult and 23,500 pediatric extracorporeal circulation procedures in 2025, serving a market where approximately 330 million individuals are affected by cardiovascular disease.